Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients
Files
Publication date
2019-02
Authors
Simsek, Melek
Meijer, Berrie
Ramsoekh, Dewkoemar
Bouma, Gerd
van der Wouden, Egbert-Jan
den Hartog, Bert
de Vries, Annemarie C
Hoentjen, Frank
Dijkstra, Gerard
de Boer, Sybrand Y
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD). 1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown. 2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.
Keywords
Taverne, Gastroenterology, Hepatology
Citation
Simsek, M, Meijer, B, Ramsoekh, D, Bouma, G, van der Wouden, E-J, den Hartog, B, de Vries, A C, Hoentjen, F, Dijkstra, G, de Boer, S Y, Jansen, J M, van der Meulen, A E, Beukers, R, Brink, M A, Steinhauser, T, Oldenburg, B, Gilissen, L P, Naber, T H, Verhagen, M A, de Boer, N K H, Mulder, C J J & Dutch Initiative on Crohn and Colitis (ICC) 2019, 'Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients', Clinical Gastroenterology and Hepatology, vol. 17, no. 3, pp. 568-570. https://doi.org/10.1016/j.cgh.2018.05.009